探讨二甲胺环素辅助治疗抑郁症12周后白细胞介素-6、脂多糖结合蛋白和脑源性神经营养因子的变化。

IF 3.8 4区 医学 Q1 Medicine
Acta Neuropsychiatrica Pub Date : 2022-08-01 Epub Date: 2021-12-23 DOI:10.1017/neu.2021.44
Kyoko Hasebe, Mohammadreza Mohebbi, Laura Gray, Adam J Walker, Chiara C Bortolasci, Alyna Turner, Michael Berk, Ken Walder, Michael Maes, Buranee Kanchanatawan, Melanie M Ashton, Lesley Berk, Chee H Ng, Gin S Malhi, Ajeet B Singh, Olivia M Dean
{"title":"探讨二甲胺环素辅助治疗抑郁症12周后白细胞介素-6、脂多糖结合蛋白和脑源性神经营养因子的变化。","authors":"Kyoko Hasebe,&nbsp;Mohammadreza Mohebbi,&nbsp;Laura Gray,&nbsp;Adam J Walker,&nbsp;Chiara C Bortolasci,&nbsp;Alyna Turner,&nbsp;Michael Berk,&nbsp;Ken Walder,&nbsp;Michael Maes,&nbsp;Buranee Kanchanatawan,&nbsp;Melanie M Ashton,&nbsp;Lesley Berk,&nbsp;Chee H Ng,&nbsp;Gin S Malhi,&nbsp;Ajeet B Singh,&nbsp;Olivia M Dean","doi":"10.1017/neu.2021.44","DOIUrl":null,"url":null,"abstract":"<p><p>This study aimed to explore effects of adjunctive minocycline treatment on inflammatory and neurogenesis markers in major depressive disorder (MDD). Serum samples were collected from a randomised, placebo-controlled 12-week clinical trial of minocycline (200 mg/day, added to treatment as usual) for adults (<i>n</i> = 71) experiencing MDD to determine changes in interleukin-6 (IL-6), lipopolysaccharide binding protein (LBP) and brain derived neurotrophic factor (BDNF). General Estimate Equation modelling explored moderation effects of baseline markers and exploratory analyses investigated associations between markers and clinical outcomes. There was no difference between adjunctive minocycline or placebo groups at baseline or week 12 in the levels of IL-6 (week 12; placebo 2.06 ± 1.35 pg/ml; minocycline 1.77 ± 0.79 pg/ml; <i>p</i> = 0.317), LBP (week 12; placebo 3.74 ± 0.95 µg/ml; minocycline 3.93 ± 1.33 µg/ml; <i>p</i> = 0.525) or BDNF (week 12; placebo 24.28 ± 6.69 ng/ml; minocycline 26.56 ± 5.45 ng/ml; <i>p</i> = 0.161). Higher IL-6 levels at baseline were a predictor of greater clinical improvement. Exploratory analyses suggested that the change in IL-6 levels were significantly associated with anxiety symptoms (HAMA; <i>p</i> = 0.021) and quality of life (Q-LES-Q-SF; <i>p</i> = 0.023) scale scores. No other clinical outcomes were shown to have this mediation effect, nor did the other markers (LBP or BDNF) moderate clinical outcomes. There were no overall changes in IL-6, LBP or BDNF following adjunctive minocycline treatment. Exploratory analyses suggest a potential role of IL-6 on mediating anxiety symptoms with MDD. Future trials may consider enrichment of recruitment by identifying several markers or a panel of factors to better represent an inflammatory phenotype in MDD with larger sample size.</p>","PeriodicalId":7066,"journal":{"name":"Acta Neuropsychiatrica","volume":null,"pages":null},"PeriodicalIF":3.8000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Exploring interleukin-6, lipopolysaccharide-binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression.\",\"authors\":\"Kyoko Hasebe,&nbsp;Mohammadreza Mohebbi,&nbsp;Laura Gray,&nbsp;Adam J Walker,&nbsp;Chiara C Bortolasci,&nbsp;Alyna Turner,&nbsp;Michael Berk,&nbsp;Ken Walder,&nbsp;Michael Maes,&nbsp;Buranee Kanchanatawan,&nbsp;Melanie M Ashton,&nbsp;Lesley Berk,&nbsp;Chee H Ng,&nbsp;Gin S Malhi,&nbsp;Ajeet B Singh,&nbsp;Olivia M Dean\",\"doi\":\"10.1017/neu.2021.44\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This study aimed to explore effects of adjunctive minocycline treatment on inflammatory and neurogenesis markers in major depressive disorder (MDD). Serum samples were collected from a randomised, placebo-controlled 12-week clinical trial of minocycline (200 mg/day, added to treatment as usual) for adults (<i>n</i> = 71) experiencing MDD to determine changes in interleukin-6 (IL-6), lipopolysaccharide binding protein (LBP) and brain derived neurotrophic factor (BDNF). General Estimate Equation modelling explored moderation effects of baseline markers and exploratory analyses investigated associations between markers and clinical outcomes. There was no difference between adjunctive minocycline or placebo groups at baseline or week 12 in the levels of IL-6 (week 12; placebo 2.06 ± 1.35 pg/ml; minocycline 1.77 ± 0.79 pg/ml; <i>p</i> = 0.317), LBP (week 12; placebo 3.74 ± 0.95 µg/ml; minocycline 3.93 ± 1.33 µg/ml; <i>p</i> = 0.525) or BDNF (week 12; placebo 24.28 ± 6.69 ng/ml; minocycline 26.56 ± 5.45 ng/ml; <i>p</i> = 0.161). Higher IL-6 levels at baseline were a predictor of greater clinical improvement. Exploratory analyses suggested that the change in IL-6 levels were significantly associated with anxiety symptoms (HAMA; <i>p</i> = 0.021) and quality of life (Q-LES-Q-SF; <i>p</i> = 0.023) scale scores. No other clinical outcomes were shown to have this mediation effect, nor did the other markers (LBP or BDNF) moderate clinical outcomes. There were no overall changes in IL-6, LBP or BDNF following adjunctive minocycline treatment. Exploratory analyses suggest a potential role of IL-6 on mediating anxiety symptoms with MDD. Future trials may consider enrichment of recruitment by identifying several markers or a panel of factors to better represent an inflammatory phenotype in MDD with larger sample size.</p>\",\"PeriodicalId\":7066,\"journal\":{\"name\":\"Acta Neuropsychiatrica\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2022-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Neuropsychiatrica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1017/neu.2021.44\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/12/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Neuropsychiatrica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/neu.2021.44","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/12/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 4

摘要

本研究旨在探讨辅助二甲胺环素治疗对重度抑郁症(MDD)炎症和神经发生标志物的影响。在一项随机、安慰剂对照的12周临床试验中,对患有重度抑郁症(MDD)的成人(n = 71)进行米诺环素(200 mg/天,常规治疗中添加)的血清样本收集,以确定白细胞介素-6 (IL-6)、脂多糖结合蛋白(LBP)和脑源性神经营养因子(BDNF)的变化。一般估计方程模型探讨了基线标记物的调节作用,探索性分析研究了标记物与临床结果之间的关系。辅助二甲胺四环素组和安慰剂组在基线或第12周时IL-6水平无差异(第12周;安慰剂2.06±1.35 pg/ml;米诺环素1.77±0.79 pg/ml;p = 0.317), LBP(第12周;安慰剂3.74±0.95µg/ml;米诺环素3.93±1.33µg/ml;p = 0.525)或BDNF(第12周;安慰剂24.28±6.69 ng/ml;米诺环素26.56±5.45 ng/ml;P = 0.161)。基线时较高的IL-6水平预示着更大的临床改善。探索性分析表明,IL-6水平的变化与焦虑症状显著相关(HAMA;p = 0.021)和生活质量(Q-LES-Q-SF;P = 0.023)量表得分。没有其他临床结果显示有这种中介作用,其他标记物(LBP或BDNF)也没有调节临床结果。辅助二甲胺四环素治疗后,IL-6、LBP或BDNF总体上没有变化。探索性分析提示IL-6在MDD焦虑症状介导中的潜在作用。未来的试验可能会考虑通过确定几个标记物或一组因素来丰富招募,以便在样本量更大的情况下更好地代表MDD的炎症表型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Exploring interleukin-6, lipopolysaccharide-binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression.

This study aimed to explore effects of adjunctive minocycline treatment on inflammatory and neurogenesis markers in major depressive disorder (MDD). Serum samples were collected from a randomised, placebo-controlled 12-week clinical trial of minocycline (200 mg/day, added to treatment as usual) for adults (n = 71) experiencing MDD to determine changes in interleukin-6 (IL-6), lipopolysaccharide binding protein (LBP) and brain derived neurotrophic factor (BDNF). General Estimate Equation modelling explored moderation effects of baseline markers and exploratory analyses investigated associations between markers and clinical outcomes. There was no difference between adjunctive minocycline or placebo groups at baseline or week 12 in the levels of IL-6 (week 12; placebo 2.06 ± 1.35 pg/ml; minocycline 1.77 ± 0.79 pg/ml; p = 0.317), LBP (week 12; placebo 3.74 ± 0.95 µg/ml; minocycline 3.93 ± 1.33 µg/ml; p = 0.525) or BDNF (week 12; placebo 24.28 ± 6.69 ng/ml; minocycline 26.56 ± 5.45 ng/ml; p = 0.161). Higher IL-6 levels at baseline were a predictor of greater clinical improvement. Exploratory analyses suggested that the change in IL-6 levels were significantly associated with anxiety symptoms (HAMA; p = 0.021) and quality of life (Q-LES-Q-SF; p = 0.023) scale scores. No other clinical outcomes were shown to have this mediation effect, nor did the other markers (LBP or BDNF) moderate clinical outcomes. There were no overall changes in IL-6, LBP or BDNF following adjunctive minocycline treatment. Exploratory analyses suggest a potential role of IL-6 on mediating anxiety symptoms with MDD. Future trials may consider enrichment of recruitment by identifying several markers or a panel of factors to better represent an inflammatory phenotype in MDD with larger sample size.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Acta Neuropsychiatrica
Acta Neuropsychiatrica 医学-精神病学
CiteScore
8.50
自引率
5.30%
发文量
30
审稿时长
6-12 weeks
期刊介绍: Acta Neuropsychiatrica is an international journal focussing on translational neuropsychiatry. It publishes high-quality original research papers and reviews. The Journal''s scope specifically highlights the pathway from discovery to clinical applications, healthcare and global health that can be viewed broadly as the spectrum of work that marks the pathway from discovery to global health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信